Key result
CDMT yields similar RV recovery and safety in cancer-associated PE compared to noncancer patients.
Why the study?
Cancer-associated pulmonary embolism contributes significantly to morbidity and mortality, but data regarding catheter-directed mechanical thrombectomy in patients with cancer are limited.
Does catheter-directed mechanical thrombectomy (CDMT) improve RV function and maintain safety in patients with intermediate-high or high-risk pulmonary embolism and cancer compared to nononcologic patients?
Observational (n=290)
Yes
Does catheter-directed mechanical thrombectomy (CDMT) improve RV function and maintain safety in patients with intermediate-high or high-risk pulmonary embolism and cancer compared to nononcologic patients?
p-value: p=.383
Catheter-directed mechanical thrombectomy is a safe and effective treatment for intermediate-high or high-risk pulmonary embolism in patients with cancer, yielding outcomes comparable to those without cancer.
Supports feasibility of CDMT in cancer-associated intermediate-high/high-risk PE; leaves open need for RCTs versus anticoagulation.
Background: Cancer-associated pulmonary embolism (PE) is a commonplace complication that contributes to morbidity and mortality. Data of catheter-directed mechanical thrombectomy (CDMT) in patients with cancer are limited. Objectives: To assess the efficacy and safety of CDMT in patients with intermediate-high or high-risk PE and cancer comorbidity. Methods: Multicenter prospective, observational study of 290 PE patients treated with CDMT using continuous vacuum aspiration thrombectomy systems. Patients were classified into 2 groups: oncologic patients (OP) and nononcologic patients (NOP). The primary safety endpoints included in-hospital all-cause mortality and procedure-related major bleeding. The primary efficacy endpoint was the change in right-to-left-ventricle (RV/LV) ratio before and 48 hours after CDMT. The efficacy and safety of CDMT were compared between OP and NOP. Conclusions: CDMT in OP characterized an acceptable safety profile and substantial improvement in RV function, similar to those observed in NOP. Patients with cancer-related PE had similar in-hospital survival rate compared with patients without cancer, when treated with CDMT.
No takes yet. Share an insight, caveat, or question.
Banaszkiewicz et al. (2026) conducted an observational in Intermediate-high or high-risk pulmonary embolism (n=290). Cancer comorbidity (oncologic patients) vs. Nononcologic patients was evaluated on Change in right-to-left-ventricle (RV/LV) ratio before and 48 hours after CDMT (efficacy); in-hospital all-cause mortality and procedure-related major bleeding (safety) (p=.383). Catheter-directed mechanical thrombectomy in patients with cancer-associated pulmonary embolism demonstrated an acceptable safety profile and substantial improvement in RV function, similar to patients without cancer.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: